ContraFect Corporation (NASDAQ:CFRX) Files An 8-K Other Events
Item 8.01 Other Events.
On February 24, 2020, ContraFect Corporation (the Company) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for exebacase for the treatment of MRSA bacteremia, including right-sided endocarditis, when used in addition to standard-of-care anti-staphylococcal antibiotics in adult patients.The full text of the press release issued in connection with this announcement is filed as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 | Press Release issued on February 24, 2020 |